ImmunityBio Builds Industrial Workforce with the Appointment of Seasoned Advertising and Reimbursement Executives

Biopharma leaders deliver verified market place progress talents in urology and oncology to bolster company’s commercialization system and extensive-phrase growth plans

  • Helen Luu, previous CEO of Cell BT, is named ImmunityBio’s 1st Chief Commercial Officer and brings a robust background in product or service commercialization in the urology industry, business growth, income expansion, and oncology industry growth.

  • Sigrid Schreiner joins as Senior Vice President of World Market place Obtain, including decades of market entry encounter to the leadership team, like the sector start of chemotherapy Abraxane®.

CULVER City, Calif., September 07, 2021–(Company WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a medical-stage immunotherapy company, now introduced two important government appointments that bring field-main marketplace progress and accessibility experience to the corporation. Helen Luu will provide as the company’s very first Main Business Officer, joining ImmunityBio from her posture as CEO of Motor vehicle-T developer Mobile BT. The corporation also named Sigrid Schreiner as Senior Vice President of World-wide Market Obtain. She joins the organization from Stemline Therapeutics (now Menarini Team), a global professional-phase oncology therapeutics corporation.

“The timing is suitable for ImmunityBio to build out our commercial group and we could not have selected stronger industrial leaders than Helen and Sigrid,” claimed Richard Adcock, President and CEO, ImmunityBio. “Their mixed 35 a long time of industrial know-how in oncology therapeutics is properly aligned with our expansion strategy as we progress our Section 3 trials for bladder and lung cancer and continue to make development with our various Phase 2 trials. We are enthusiastic to have them on our team and price the electricity they will inject into this crucial part of the business.”

As Chief Business Officer, Luu will consider on the essential duties of the company’s world industrial method, including the structure and execution of enlargement into the oncology and urology marketplaces, as very well as developing important exterior alliances to assist the professional accomplishment of ImmunityBio. With far more than 16 many years of encounter in multichannel and specialty biotech operations, Luu thrives in fast altering, highly competitive environments and specializes in small business enhancement, corporate restructuring, product sales optimization, and system advancement to drive corporate revenue.

“I am thrilled to join ImmunityBio at this enjoyable time as the firm strategies the potential world start of the company’s oncology portfolio,” explained Helen. “And I appear ahead to operating with the ImmunityBio leadership group to make sure sufferers all around the earth will have access to the company’s modern therapies.”

Luu joined Cell BT as its very first Chief Running Officer in which she was dependable for directing the company’s strategic positioning and functions, as very well as expanding the scope of its pipeline. Prior to Cell BT, Luu was the head of company advancement at Dendreon, the foremost innovator of immunotherapy for the remedy of prostate most cancers. In the course of her 10-year tenure at Dendreon, she held many commercial management roles and tasks, which include the successful launch of the nationwide urologic oncology hospital gross sales team to strategically accelerate profits expansion. Luu commenced her biotech profession at Gilead Sciences and was the top gross sales contributor for 3 consecutive years.

Schreiner provides additional than 25 many years of biopharma knowledge to ImmunityBio. She will be responsible for developing the company’s world-wide payer, reimbursement, and distribution methods, as nicely as running individual obtain and crucial accounts.

Prior to her function at Stemline Therapeutics, Schreiner held marketplace accessibility roles with Dendreon, Lash Group (AmerisourceBergen), Immunex, and CTI Biopharma. She also led strategic preparing and procedure improvement tasks at Deloitte Administration Consulting for health designs and physician corporations.

Luu joins ImmunityBio powerful September 7, 2021, while Schreiner joins the enterprise successful September 13, 2021.

About ImmunityBio

ImmunityBio is a foremost late-clinical-phase immunotherapy corporation building subsequent-generation therapies that generate immunogenic mechanisms for defeating cancers and infectious disorders. The company’s immunotherapy platform activates both the innate (organic killer cell and macrophage) and adaptive (T mobile) immune systems to generate extensive-expression “immunological memory.”

ImmunityBio has a in depth immunotherapy pipeline with more than 40 medical trials (firm sponsored or investigator initiated)—of which 25 are at Period II and III levels of development—across 19 indications in solid and liquid cancers and infectious disorders. Currently 17 initial-in-human immunotherapy agents are in scientific testing and, to date, around 1,800 clients have been researched with our antibody cytokine fusion proteins, albumin chemo immunomodulators, Adeno and yeast vaccines and our off-the-shelf pure killer mobile solutions. Anktiva™ (ImmunityBio’s guide cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist sophisticated and has obtained Breakthrough Remedy and Quick Keep track of Designations from the U.S. Food items and Drug Administration (Food and drug administration) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC).

The company’s platforms are based mostly on the basis of four separate modalities: Antibody cytokine fusion proteins, synthetic immunomodulators, 2nd-era human adenovirus (Experienced5) and yeast vaccine technologies, and condition-of-the-artwork, off-the-shelf natural killer cells, like autologous and allogenic cytokine-improved memory NK cells. ImmunityBio is at the moment developing a dual assemble COVID-19 vaccine applicant working with its Had5 platform.

ImmunityBio is a primary producer of cryopreserved and clinical dose types of off-the-shelf all-natural killer (NK) cell therapies. The organization has proven GMP producing ability at scale with reducing-edge mobile production know-how and all set-to-scale facilities, as very well as intensive and seasoned R&D, medical trial, and regulatory functions and progress groups. For extra information and facts, make sure you stop by: www.immunitybio.com

Ahead On the lookout Statements

This push launch includes forward-on the lookout statements within just the that means of the Personal Securities Litigation Reform Act of 1995, these kinds of as statements regarding the growth of therapeutics for cancer and infectious health conditions, the improvement of our Phase II and III trials, and regulatory approval, commercialization and commercial achievements of ImmunityBio’s solution candidates and related matters. Statements in this press launch that are not statements of historic fact are regarded as ahead-looking statements, which are normally determined by the use of terms these as “anticipates,” “thinks,” “continues”, “could”, “estimates,” “expects,” “intends,” “may perhaps,” “designs,” “prospective”, “predicts”, “initiatives,” “seeks,” “need to,” “will,” and variants of such words or identical expressions. Statements of past efficiency, efforts, or outcomes of our medical trials, about which inferences or assumptions could be built, can also be ahead-on the lookout statements and are not indicative of upcoming overall performance or benefits. Ahead-looking statements are neither forecasts, claims nor ensures, and are dependent on the existing beliefs of ImmunityBio’s management as perfectly as assumptions produced by and info presently accessible to ImmunityBio. This kind of statements reflect the current sights of ImmunityBio with regard to long run activities and are subject to known and unfamiliar hazards, which include organization, regulatory, financial and competitive hazards, uncertainties, contingencies and assumptions about ImmunityBio, including, with no limitation, (i) the skill of ImmunityBio to proceed its prepared preclinical and scientific enhancement of its improvement applications, and the timing and achievements of any such continued preclinical and scientific improvement and planned regulatory submissions, (ii) inability to keep and seek the services of essential staff, (iii) uncertainty of the envisioned fiscal performance and productive integration of the merged organization subsequent completion of the current merger of ImmunityBio with NantCell (the “Merger”), which includes the possibility that the envisioned synergies and price creation from the Merger will not be understood or will not be recognized inside the expected time interval, (iv) whether interim, initial, “prime-line” and preliminary info from ImmunityBio’s clinical trials that it announces or publishes from time to time may well modify as extra individual facts come to be obtainable and are matter to audit and verification techniques that could outcome in material alterations in the last details, (v) ImmunityBio’s skill to attain supplemental funding to fund its functions and complete the enhancement and commercialization of its different merchandise candidates, (vi) ImmunityBio’s capability to obtain, sustain, guard and enforce patent safety and other proprietary legal rights for its item candidates and technologies, (vii) ImmunityBio’s means to productively commercialize its merchandise candidates and (viii) the unidentified long term affect of the COVID-19 pandemic hold off on specified scientific trials or their milestones and/or ImmunityBio’s operations or running bills. A lot more details about these and other challenges that may perhaps impression ImmunityBio’s company are described beneath the heading “Threat Components” in the Company’s Variety 8-K submitted with the U.S. Securities and Trade Commission (“SEC”) on March 10, 2021, Sort 10-Q filed with the SEC on August 12, 2021 and in subsequent filings built by ImmunityBio with the SEC, which are out there on the SEC’s site at www.sec.gov. ImmunityBio cautions you not to location undue reliance on any ahead-looking statements, which speak only as of the day hereof. ImmunityBio does not undertake any duty to update any ahead-looking statement or other data in this push release, other than to the extent required by legislation.

See resource model on businesswire.com: https://www.businesswire.com/information/dwelling/20210907005330/en/

Contacts

Investors
Sarah Singleton
ImmunityBio, Inc.
844-696-5235, Solution 5

Media
Katie Dodge
Salutem
978-360-3151
Katie.Dodge@salutemcomms.com